Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 1-3/2010

01-12-2010

HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma

Authors: Marta Epeldegui, Elena Vendrame, Otoniel Martínez-Maza

Published in: Immunologic Research | Issue 1-3/2010

Login to get access

Abstract

HIV infection is associated with a much higher risk for the development of non-Hodgkin lymphoma (AIDS-NHL). The principal causes of lymphomagenesis in HIV-infected individuals are thought to be the loss of immune function seen in HIV infection, which results in the loss of immunoregulation of Epstein–Barr virus-infected B cells, as well as HIV infection-associated immune dysregulation, including chronic B-cell activation. In this review, we discuss recent reports that further support the importance of these factors, and we highlight emerging evidence of different mechanisms that potentially drive lymphomagenesis in HIV-infected individuals.
Literature
1.
Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67.CrossRefPubMed
2.
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1–19.
3.
Raphaël M, Said J, Borish B, et al. Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumors of the haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
4.
Carbone A, Cesarman E, Spina M, et al. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113:1213–24.CrossRefPubMed
5.
Klein G, Klein E, Kashuba E. Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes. Biochem Biophys Res Commun. 2010;396:67–73.CrossRefPubMed
6.
Bornkamm GW. Epstein-Barr virus and the pathogenesis of Burkitt’s lymphoma: more questions than answers. Int J Cancer. 2009;124:1745–55.CrossRefPubMed
7.
Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol. 2010;149:484–97.CrossRefPubMed
8.
Polo JM, Juszczynski P, Monti S, et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci USA. 2007;104:3207–12.CrossRefPubMed
9.
Deffenbacher KE, Iqbal J, Liu Z, et al. Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression. J Acquir Immune Defic Syndr. 2010;54:18–26.CrossRefPubMed
10.
Martinez-Maza O, Crabb E, Mitsuyasu RT, et al. Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J Immunol. 1987;138:3720–4.PubMed
11.
Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet. 2008;40:108–12.CrossRefPubMed
12.
Robbiani DF, Bunting S, Feldhahn N, et al. AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. Mol Cell. 2009;36:631–41.CrossRefPubMed
13.
Epeldegui M, Breen EC, Hung YP, et al. Elevated expression of activation induced cytidine deaminase in peripheral blood mononuclear cells precedes AIDS-NHL diagnosis. AIDS. 2007;21:2265–70.CrossRefPubMed
14.
Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol. 2010;28:773–9.CrossRefPubMed
15.
Gottenberg JE, Aucouturier F, Goetz J, et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren’s syndrome. Ann Rheum Dis. 2007;66:23–7.CrossRefPubMed
16.
Martin W, Abraham R, Shanafelt T, et al. Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Transl Res. 2007;149:231–5.CrossRefPubMed
17.
Terrier B, Sene D, Saadoun D, et al. Serum-free light chain assessment in hepatitis C virus-related lymphoproliferative disorders. Ann Rheum Dis. 2009;68:89–93.CrossRefPubMed
18.
Breen EC, Fatahi S, Epeldegui M, et al. Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin’s B cell lymphoma. Tumour Biol. 2006;27:187–94.CrossRefPubMed
19.
Widney D, Gundapp G, Said JW, et al. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol. 1999;93:114–23.CrossRefPubMed
20.
Chiarle R, Podda A, Prolla G, et al. CD30 in normal and neoplastic cells. Clin Immunol. 1999;90:157–64.CrossRefPubMed
21.
van Oers MH, Pals ST, Evers LM, et al. Expression and release of CD27 in human B-cell malignancies. Blood. 1993;82:3430–6.PubMed
22.
De Milito A, Morch C, Sonnerborg A, et al. Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS. 2001;15:957–64.CrossRefPubMed
23.
Breen EC, Epeldegui M, Boscardin WJ, et al. Elevated levels of soluble CD44 precede the development of AIDS-associated non-Hodgkin’s B-cell lymphoma. Aids. 2005;19:1711–2.CrossRefPubMed
24.
Navarro JT, Ribera JM, Vaquero M, et al. Increased serum levels of CD44s and CD44v6 in patients with AIDS-related non-Hodgkin’s lymphoma. AIDS. 2000;14:1460–1.CrossRefPubMed
25.
Yawetz S, Cumberland WG, van der Meyden M, et al. Elevated serum levels of soluble CD23 (sCD23) precede the appearance of acquired immunodeficiency syndrome–associated non-Hodgkin’s lymphoma. Blood. 1995;85:1843–9.PubMed
26.
Schroeder JR, Saah AJ, Hoover DR, et al. Serum soluble CD23 level correlates with subsequent development of AIDS-related non-Hodgkin’s lymphoma. Cancer Epidemiol Biomarkers Prev. 1999;8:979–84.PubMed
27.
Schroeder JR, Saah AJ, Ambinder RF, et al. Serum sCD23 level in patients with AIDS-related non-Hodgkin’s lymphoma is associated with absence of Epstein-Barr virus in tumor tissue. Clin Immunol. 1999;93:239–44.CrossRefPubMed
28.
Gordon J, Millsum MJ, Flores-Romo L, et al. Regulation of resting and cycling human B lymphocytes via surface IgM and the accessory molecules interleukin-4, CD23 and CD40. Immunology. 1989;68:526–31.PubMed
29.
Gordon J, Flores-Romo L, Cairns JA, et al. CD23: a multi-functional receptor/lymphokine? Immunol Today. 1989;10:153–7.CrossRefPubMed
30.
Herbelin A, Elhadad S, Ouaaz F, et al. Soluble CD23 potentiates interleukin-1-induced secretion of interleukin-6 and interleukin-1 receptor antagonist by human monocytes. Eur J Immunol. 1994;24:1869–73.CrossRefPubMed
31.
Breen EC, van der Meijden M, Cumberland W, et al. The development of AIDS-associated Burkitt’s/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6. Clin Immunol. 1999;92:293–9.CrossRefPubMed
32.
Pluda JM, Venzon DJ, Tosato G, et al. Parameters affecting the development of non-Hodgkin’s lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol. 1993;11:1099–107.PubMed
33.
Burdin N, Van Kooten C, Galibert L, et al. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J Immunol. 1995;154:2533–44.PubMed
34.
Widney DP, Breen EC, Boscardin WJ, et al. Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. J Interferon Cytokine Res. 2005;25:702–6.CrossRefPubMed
35.
Cagigi A, Mowafi F, Phuong Dang LV, et al. Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection. Blood. 2008;112:4401–10.CrossRefPubMed
36.
Widney DP, Gui D, Popoviciu LM, et al. Expression of the B cell chemokine, CXCL13, in AIDS-associated non-Hodgkin’s lymphoma. AIDS Res Treat. 2010 (in press).
37.
Hussain SK, Widney D, Jacobson L, et al. Elevated serum levels of CXCL13 precede HIV-associated non Hodgkin’s lymphoma: 12th international conference on malignancies in aids and other acquired immunodeficiencies (ICMAOI). Bethesda, Maryland: National Cancer Institute; 2010.
38.
Fischer L, Korfel A, Pfeiffer S, et al. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res. 2009;15:5968–73.CrossRefPubMed
39.
Levin LI, Breen EC, Kitchen CR, et al. Elevated serum levels of CXCL13 precede the diagnosis of B cells non-Hodgkin lymphoma (NHL): the future of molecular epidemiology: new tools, biomarkers, and opportunities. Miami, FL: American Association for Cancer Research; 2010, 45 PR41.
40.
Breen EC, Boscardin WJ, Detels R, et al. Non-Hodgkin’s B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter-592 C/C genotype. Clin Immunol. 2003;109:119–29.CrossRefPubMed
41.
Wong HL, Breen EC, Pfeiffer RM, et al. Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study. AIDS. 2010;24:1025–33.CrossRefPubMed
42.
Sasson SC, Smith S, Seddiki N, et al. IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. Cytokine. 2010;50:58–68.CrossRefPubMed
43.
Aissani B, Ogwaro KM, Shrestha S, et al. The major histocompatibility complex conserved extended haplotype 8.1 in AIDS-related non-Hodgkin lymphoma. J Acquir Immune Defic Syndr. 2009;52:170–9.CrossRefPubMed
44.
Patke CL, Shearer WT. gp120- and TNF-alpha-induced modulation of human B cell function: proliferation, cyclic AMP generation, Ig production, and B-cell receptor expression. J Allergy Clin Immunol. 2000;105:975–82.CrossRefPubMed
45.
Romagnani S, Maggi E, Liotta F, et al. Properties and origin of human Th17 cells. Mol Immunol. 2009;47:3–7.CrossRefPubMed
46.
Takagi R, Higashi T, Hashimoto K, et al. B cell chemoattractant CXCL13 is preferentially expressed by human Th17 cell clones. J Immunol. 2008;181:186–9.PubMed
47.
Kryczek I, Wei S, Zou L, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007;178:6730–3.PubMed
48.
Ekstrom Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111:4029–38.CrossRefPubMed
49.
Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol. 2003;3:609–20.CrossRefPubMed
50.
51.
Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989;170:2081–95.CrossRefPubMed
52.
Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007;13:139–45.CrossRefPubMed
53.
Ji Y, Zhang W. Th17 cells: positive or negative role in tumor? Cancer Immunol Immunother. 2010;59:979–87.CrossRefPubMed
54.
Kim CH, Lim HW, Kim JR, et al. Unique gene expression program of human germinal center T helper cells. Blood. 2004;104:1952–60.CrossRefPubMed
55.
Vissers JL, Hartgers FC, Lindhout E, et al. BLC (CXCL13) is expressed by different dendritic cell subsets in vitro and in vivo. Eur J Immunol. 2001;31:1544–9.CrossRefPubMed
56.
Huysentruyt LC, McGrath MS. The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma. J Leukoc Biol. 2010;87:627–32.CrossRefPubMed
57.
van Baarle D, Hovenkamp E, Callan MF, et al. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood. 2001;98:146–55.CrossRefPubMed
58.
Kinlen L. Immunosuppression and cancer. In: Vainio H, Magee PN, McGregor DB, McMichael AJ, editors. Mechanisms of carcinogenesis in risk identification. Lyon: International Agency for Research on Cancer; 1992. p. 237–53.
59.
Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296:2823–31.CrossRefPubMed
60.
Gaidano G, Capello D, Carbone A. The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis. Semin Oncol. 2000;27:431–41.PubMed
61.
Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99:962–72.CrossRefPubMed
62.
Klein U, Klein G, Ehlin-Henriksson B, et al. Burkitt’s lymphoma is a malignancy of mature B cells expressing somatically mutated V region genes. Mol Med. 1995;1:495–505.PubMed
63.
Chapman CJ, Wright D, Stevenson FK. Insight into Burkitt’s lymphoma from immunoglobulin variable region gene analysis. Leuk Lymphoma. 1998;30:257–67.PubMed
64.
Bellan C, Lazzi S, Hummel M, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood. 2005;106:1031–6.CrossRefPubMed
65.
Kurth J, Hansmann ML, Rajewsky K, et al. Epstein-Barr virus-infected B cells expanding in germinal centers of infectious mononucleosis patients do not participate in the germinal center reaction. Proc Natl Acad Sci USA. 2003;100:4730–5.CrossRefPubMed
66.
Kurth J, Spieker T, Wustrow J, et al. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity. 2000;13:485–95.CrossRefPubMed
67.
Bornkamm GW. Epstein-Barr virus and its role in the pathogenesis of Burkitt’s lymphoma: an unresolved issue. Semin Cancer Biol. 2009;19:351–65.CrossRefPubMed
68.
Souza TA, Stollar BD, Sullivan JL, et al. Influence of EBV on the peripheral blood memory B cell compartment. J Immunol. 2007;179:3153–60.PubMed
69.
Souza TA, Stollar BD, Sullivan JL, et al. Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc Natl Acad Sci USA. 2005;102:18093–8.CrossRefPubMed
70.
Epeldegui M, Hung YP, McQuay A, et al. Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation-inducing molecules and in the accrual of oncogene mutations. Mol Immunol. 2007;44:934–42.CrossRefPubMed
71.
He B, Raab-Traub N, Casali P, et al. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol. 2003;171:5215–24.PubMed
72.
Gil Y, Levy-Nabot S, Steinitz M, et al. Somatic mutations and activation-induced cytidine deaminase (AID) expression in established rheumatoid factor-producing lymphoblastoid cell line. Mol Immunol. 2007;44:494–505.CrossRefPubMed
73.
Tobollik S, Meyer L, Buettner M, et al. Epstein-Barr virus nuclear antigen 2 inhibits AID expression during EBV-driven B-cell growth. Blood. 2006;108:3859–64.CrossRefPubMed
74.
Canaan A, Haviv I, Urban AE, et al. EBNA1 regulates cellular gene expression by binding cellular promoters. Proc Natl Acad Sci USA. 2009;106:22421–6.CrossRefPubMed
75.
De Falco G, Antonicelli G, Onnis A, et al. Role of EBV in microRNA dysregulation in Burkitt lymphoma. Semin Cancer Biol. 2009;19:401–6.CrossRefPubMed
76.
Mrazek J, Kreutmayer SB, Grasser FA, et al. Subtractive hybridization identifies novel differentially expressed ncRNA species in EBV-infected human B cells. Nucleic Acids Res. 2007;35:73.CrossRef
77.
Cai X, Schafer A, Lu S, et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog. 2006;2:23.CrossRef
78.
Grundhoff A, Sullivan CS, Ganem D. A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses. RNA. 2006;12:733–50.CrossRefPubMed
79.
Xia T, O’Hara A, Araujo I, et al. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1–3. Cancer Res. 2008;68:1436–42.CrossRefPubMed
80.
Leucci E, Onnis A, Cocco M, et al. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. Int J Cancer. 2010;126:1316–26.PubMed
81.
Yang R, Murillo FM, Delannoy MJ, et al. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol. 2005;174:7912–9.PubMed
82.
Machida K, Cheng KT, Sung VM, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci USA. 2004;101:4262–7.CrossRefPubMed
83.
Zuckerman E, Zuckerman T, Levine AM, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med. 1997;127:423–8.PubMed
84.
Ito M, Mizoroki F, Takai K, et al. Functional phenotypes and gene expression profiles of peripheral blood mononuclear cells in chronic hepatitis C patients who developed non-Hodgkin’s B-cell lymphoma. Biochem Biophys Res Commun. 2009;390:269–72.CrossRefPubMed
85.
Chaturvedi AK, Kleinerman RA, Hildesheim A, et al. Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. J Clin Oncol. 2009;27:967–73.CrossRefPubMed
86.
Zoufaly A, Stellbrink HJ, Heiden MA, et al. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis. 2009;200:79–87.CrossRefPubMed
87.
Schnittman SM, Lane HC, Higgins SE, et al. Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. Science. 1986;233:1084–6.CrossRefPubMed
88.
He B, Qiao X, Klasse PJ, et al. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol. 2006;176:3931–41.PubMed
89.
Kundu RK, Sangiorgi F, Wu LY, et al. Expression of the human immunodeficiency virus-Tat gene in lymphoid tissues of transgenic mice is associated with B-cell lymphoma. Blood. 1999;94:275–82.PubMed
90.
Martin G, Roy J, Barat C, et al. Human immunodeficiency virus type 1-associated CD40 ligand transactivates B lymphocytes and promotes infection of CD4+ T cells. J Virol. 2007;81:5872–81.CrossRefPubMed
91.
Epeldegui M, Thapa DR, Kitchen S, et al. CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. PLos One. 2010;5:e11448.CrossRefPubMed
92.
Kolar GR, Mehta D, Pelayo R, et al. A novel human B cell subpopulation representing the initial germinal center population to express AID. Blood. 2007;109:2545–52.CrossRefPubMed
93.
94.
Meerloo T, Parmentier HK, Osterhaus AD, et al. Modulation of cell surface molecules during HIV-1 infection of H9 cells. An immunoelectron microscopic study. Aids. 1992;6:1105–16.CrossRefPubMed
95.
96.
Palacios R, Martinez-Maza O, Guy K. Monoclonal antibodies against HLA-DR antigens replace T helper cells in activation of B lymphocytes. Proc Natl Acad Sci USA. 1983;80:3456–60.CrossRefPubMed
97.
Esser MT, Graham DR, Coren LV, et al. Differential incorporation of CD45, CD80 (B7–1), CD86 (B7–2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation. J Virol. 2001;75:6173–82.CrossRefPubMed
98.
Widney D, Boscardin WJ, Kasravi A, et al. Expression and function of CD28 on Epstein-Barr virus-positive B cell lines and AIDS-associated non-Hodgkin’s lymphoma cell lines. Tumour Biol. 2003;24:82–93.CrossRefPubMed
Metadata
Title
HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma
Authors
Marta Epeldegui
Elena Vendrame
Otoniel Martínez-Maza
Publication date
01-12-2010
Publisher
Humana Press Inc
Published in
Immunologic Research / Issue 1-3/2010
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-010-8168-8

Other articles of this Issue 1-3/2010

Immunologic Research 1-3/2010 Go to the issue

OriginalPaper

Thinking about HIV: the intersection of virus, neuroinflammation and cognitive dysfunction

OriginalPaper

A challenge for the future: aging and HIV infection

OriginalPaper

Signaling through the P38 and ERK pathways: a common link between HIV replication and the immune response

OriginalPaper

Quiescent T cells and HIV: an unresolved relationship

OriginalPaper

Biology and pathophysiology of the new human retrovirus XMRV and its association with human disease

OriginalPaper

Translating insights from persistent LCMV infection into anti-HIV immunity